On April 8, 2022 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, reported that the company will present a poster at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting, which is being held April 8-13, 2022, in New Orleans, La., and virtually (Press release, Cytori Therapeutics, APR 8, 2022, View Source [SID1234611705]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation

Title: A biology-based, mathematical model to predict the response of recurrent glioblastoma to treatment with 186Re-labeled nanoliposomes

Session Title: Mathematical Models

Session Date and Time: Tuesday, April 12, 2022, 9:00 a.m. – 12:30 p.m. CT

Location: New Orleans Convention Center, Exhibit Halls D – H, Poster Section 29

Poster Board Number: 13

Permanent Abstract Number: 2742

Link to Abstract: View Source!/10517/presentation/18391

A copy of the poster presentation will be made available under the Presentations tab of the For Investors section of the Company’s website following the meeting at www.plustherapeutics.com.